Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Center for Medical Weight Loss (CMWL) vs Vita Bella

vs+2
Vita Bella
Graded #233

Lower grade

The verdict

Center for Medical Weight Loss (CMWL) takes it — 66.9/100 to 64.9/100, but only just.

Center for Medical Weight Loss (CMWL) grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Center for Medical Weight Loss (CMWL) runs a 100 percent online, physician-supervised GLP-1 program using compounded semaglutide and tirzepatide with flat any-dose pricing. Vita Bella is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueCenter for Medical Weight Loss (CMWL) +32
76
44
Dose & formulationCenter for Medical Weight Loss (CMWL) +20
72
52
Clinical oversightVita Bella +13
78
91
Labs & monitoringVita Bella +25
52
77
FulfillmentVita Bella +12
71
83
Contract termsVita Bella +27
20
47
Center for Medical Weight Loss (CMWL) · left barVita Bella · right bar

The numbers

MetricCenter for Medical Weight Loss (CMWL)Vita Bella
WeighScore66.9/10064.9/100
GradeCC
Scorecard rank#171#233
Semaglutide$149/mo (all doses, compounded)Not disclosed
Tirzepatide$239/mo (all doses, compounded)$159/mo (2.5 mg dose, plus a separate fee, compounded)
CoverageCoverage not published46 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only

Strengths

  • Very competitive flat any-dose pricing (semaglutide from 116 dollars per month, tirzepatide from 159 dollars per month)
  • Established Center for Medical Weight Loss brand with physician supervision and clinical support
  • Fast 24-hour approvals and free three to five day shipping

Where it loses points

  • Some states are ineligible and the eligible-state list is not published
  • Compounding pharmacy is not named publicly
  • Lowest per-month prices require a three-month prepaid commitment
Vita Bella

Graded #233 · C

Strengths

  • Offers both compounded semaglutide (from $109/mo) and tirzepatide (from $159/mo) at member pricing, with supplies and a B-6 add-in included
  • Genuine LegitScript-certified website (seal #4395819) and a clearly disclosed legal entity, Vita Bella Health, LLC (Nevada)
  • Broad access: care published for 46 states plus Washington, D.C., and HSA cards are accepted
  • Fully remote telehealth with video provider consults and quarterly provider check-ins included in the membership
  • Medications dispensed by US FDA-inspected compounding pharmacies; ondansetron for nausea provided at no extra charge

Where it loses points

  • Advertised $109-$159 medication prices require a separate $129/mo membership plus a one-time $99 consult, pushing true cost to ~$238-288/mo
  • Three-month minimum commitment before it renews month-to-month; no refunds on medications and all sales are final
  • Compounding pharmacy partners are not named anywhere on the site — a transparency gap
  • Compounded semaglutide and tirzepatide are not FDA-approved; only the dispensing pharmacies are described as FDA-inspected
  • Disputes are subject to binding arbitration with a class-action waiver, governed by Nevada law (Las Vegas jurisdiction)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard